PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
News|Articles|February 13, 2026
INTERPHEX: April 21-23, 2026
Elevate your industry knowledge, connect with key stakeholders, and stay at the forefront of pharmaceutical innovation at INTERPHEX.
Advertisement
Dates: April 21-23, 2026
Location: Javits Center, New York City
Description: INTERPHEX, the leading global pharmaceutical and biotechnology event that fuses industry innovation with expert-led conference. Taking place at the Javits Center NYC on April 21-23, 2026, INTERPHEX offers an expansive exhibition floor showcasing cutting-edge products and services from industry leaders. Attendees and exhibitors engage in enlightening seminars led by experts, delve into technology showcases spotlighting the latest innovations, and benefit from unparalleled networking opportunities. This dynamic platform unites professionals, fostering collaborations and providing a comprehensive view of advancements in pharmaceutical manufacturing, process development, and regulatory compliance.
Registration:
Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, detailed an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains that developing a molecule requires a holistic view of its chemical, physical, and biological properties.
Advertisement
Advertisement